Page 14 - Haematologica Vol. 109 - July 2024

EDITORIAL
A. Kumar and S. Swaminathan
is that not all individuals who acquire this translocation in utero go on to develop overt leukemia.9 The extent of IFN-I-mediated antileukemic responses by MSC may determine the risk of development of overt leukemia in individuals born with the ETV6::RUNX1 rearrangement.10 The above theories require experimental testing. Lessons learnt from the role of IFN-I in ETV6-RUNX1+ ALL will also inform the development of safer therapeutic alternatives
References
1. Smeets MWE, Orsel J, Stalpers F, et al. B-cell precursor acute lymphoblastic leukemia elicits an interferon α/b response in bone marrow-derived mesenchymal stroma. Haematologica. 2024;109(7):2073-2084.
2. Kumar A, Khani AT, Swaminathan S. Type I interferons: one stone to concurrently kill two birds, viral infections and cancers. Curr Res Virol Sci. 2021;2:100014.
3. Dunn GP, Bruce AT, Sheehan KC, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005;6(7):722-729.
4. Asmana Ningrum R. Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica (Cairo). 2014;2014:970315.
5. Arellano ML, Langston A, Winton E, Flowers CR, Waller EK. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant. 2007;13(1):116-123.
6. Kumar A, Khani AT, Duault C, et al. Intrinsic suppression of type
to direct IFN-I administration for treating higher risk BCP ALL subgroups.
Disclosures
No conflicts of interest to disclose.
Contributions
Both authors contributed equally.
I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia. J Immunother Cancer. 2023;11(5):e006649.
7. Einav U, Tabach Y, Getz G, et al. Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene. 2005;24(42):6367-6375.
8. Schrappe M, Bleckmann K, Zimmermann M, et al. Reduced- intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000). J Clin Oncol. 2018;36(3):244-253.
9. Wiemels J, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;354(9189):1499-1503.
10. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6(3):193-203.
Haematologica | 109 July 2024
2028